Vestal Point Capital LP acquired a new position in shares of GSK plc (NYSE:GSK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 300,000 shares of the pharmaceutical company's stock, valued at approximately $12,264,000. GSK comprises approximately 0.9% of Vestal Point Capital LP's holdings, making the stock its 28th largest position.
A number of other large investors have also recently made changes to their positions in GSK. Boltwood Capital Management lifted its position in shares of GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company's stock worth $429,000 after buying an additional 270 shares in the last quarter. First Affirmative Financial Network boosted its position in GSK by 4.7% in the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company's stock worth $245,000 after purchasing an additional 283 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock worth $137,000 after acquiring an additional 303 shares during the period. Mesirow Financial Investment Management Inc. boosted its stake in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock valued at $682,000 after acquiring an additional 323 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in shares of GSK by 6.3% during the 2nd quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company's stock valued at $213,000 after acquiring an additional 327 shares during the period. 15.74% of the stock is owned by institutional investors.
GSK Price Performance
Shares of GSK stock traded down $0.20 during trading on Friday, hitting $34.13. The company had a trading volume of 2,051,779 shares, compared to its average volume of 4,144,134. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92. The stock has a market capitalization of $70.74 billion, a price-to-earnings ratio of 22.16, a price-to-earnings-growth ratio of 1.31 and a beta of 0.66. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock's 50-day moving average is $37.42 and its two-hundred day moving average is $40.09.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.60%. This is a boost from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio (DPR) is 99.35%.
Insider Activity at GSK
In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm's stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares of the company's stock, valued at $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and dropped their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Barclays upgraded GSK to a "hold" rating in a research note on Tuesday, August 27th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Finally, Argus raised GSK to a "strong-buy" rating in a report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.25.
Get Our Latest Stock Report on GSK
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
